| Literature DB >> 32028720 |
Shanshan Guan1,2, Ketong Zhu1,2, Yanjiao Dong1,2, Hao Li1,2, Shuang Yang1,2, Song Wang3, Yaming Shan4.
Abstract
Streptococcus pneumoniae can cause diseases such as pneumonia. Broad-spectrum antibiotic therapy for Streptococcus pneumoniae is increasingly limited due to the emergence of drug-resistant strains. The development of novel drugs is still currently of focus. Abundant polyphenols have been demonstrated to have antivirus and antibacterial ability. Chlorogenic acid is one of the representatives that has been proven to have the potential to inhibit both the influenza virus and Streptococcus pneumoniae. However, for such a potential neuraminidase inhibitor, the interaction mechanism studies between chlorogenic acid and Streptococcus pneumoniae neuraminidase are rare. In the current study, the binding mechanism of chlorogenic acid and Streptococcus pneumoniae neuraminidase were investigated by molecular simulation. The results indicated that chlorogenic acid might establish the interaction with Streptococcus pneumoniae neuraminidase via hydrogen bonds, salt bridge, and cation-π. The vital residues involved Arg347, Ile348, Lys440, Asp372, Asp417, and Glu768. The side chain of Arg347 might form a cap-like structure to lock the chlorogenic acid to the active site. The results from binding energy calculation indicated that chlorogenic acid had strong binding potential with neuraminidase. The results predicted a detailed binding mechanism of a potential Streptococcus pneumoniae neuraminidase inhibitor, which will be provide a theoretical basis for the mechanism of new inhibitors.Entities:
Keywords: Streptococcus pneumoniae; chlorogenic acid; molecular docking; molecular dynamics simulation; neuraminidase
Mesh:
Substances:
Year: 2020 PMID: 32028720 PMCID: PMC7038148 DOI: 10.3390/ijms21031003
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Ramachandran plot of optimized Streptococcus pneumoniae neuraminidase type A (NanA) protein system.
Figure 2(a) Root-mean-square deviation (RMSD) plot of the NanA–chlorogenic acid complex during molecular dynamics simulation. (b) Average RMSD values for the system during the 50 ns molecular dynamics simulation.
Figure 3(a) Relative free energy surfaces along the first two principle components (PC1, PC2) of the NanA–chlorogenic acid complex. (b) Predicted integral binding poses of NanA–chlorogenic acid.
Figure 4(a) Predicted detail binding modes of chlorogenic acid in the NanA–chlorogenic acid complex. (b) Two-dimensional interactions between NanA and chlorogenic acid.
Hydrogen bond occupancies for the NanA–chlorogenic acid complex.
| Acceptor | Donor | Presence (%) | ||
|---|---|---|---|---|
| Chlorogenic acid | O7 | Arg347 | N-H | 19.6% |
| Chlorogenic acid | O8 | le348 | N-H | 58.4% |
| Asp372 | COO- | Chlorogenic acid | O-H | 78.4% |
| Chlorogenic acid | O2 | Asp417 | O-H | 67.3% |
| Glu768 | COO- | Chlorogenic acid | O-H | 99.9% |
Figure 5Distribution of hydrogen bond numbers between NanA and chlorogenic acid.
Figure 6The detail interaction between chlorogenic acid and Arg347/Lys440.
Figure 7Binding energy contributions of Arg347 and Lys440.
Figure 8The distances between predicted residues of NanA and chlorogenic acid during 50 ns simulation.
Calculation of binding free energy using molecular mechanics Poisson–Boltzmann surface area (MM-PBSA).
| Energy Components | Values (kJ/mol) |
|---|---|
| Van der Waals energy | −140.06 ± 15.42 |
| Electrostatic energy | −953.77 ± 32.38 |
| Polar solvation energy | 282.28 ± 25.02 |
| SASA energy | −17.89 ± 0.78 |
| Binding energy | −829.44 ± 19.31 |
Figure 9(a) The salt bridge between Arg366 and Asp372/Asp364. (b) The monitored distance between Arg366 and Asp372/Asp364.
Figure 10(a) The side chain direction of Asp372 and Arg366 in complex-NanA and free-NanA; (b) the radius of gyration of the loop in which Asp372 and Arg366 were located in complex-NanA and free-NanA.
Figure 11The difference of binding energy contribution from van der Waals and electrostatic energy in the NanA–chlorogenic acid and NanA–zanamivir complexes.